Inhibitex, Inc. (NASDAQ:INHX); (the “Company”) today announced
its financial results for the second quarter ended June 30, 2011
and provided an update on several recent clinical and corporate
developments.
As of June 30, 2011, the Company held $58 million in cash, cash
equivalents and short and long-term investments. The Company
reported a net loss in the second quarter of 2011 of $5.3 million
or ($0.07) per share.
“We look forward to initiating a Phase 2 clinical trial next
week to evaluate the safety, tolerability and antiviral activity of
INX-189 administered in combination with standard of care therapy
for 12 weeks in HCV-infected genotype 2 and 3 patients,” stated
Russell H. Plumb, President and CEO of Inhibitex, Inc. “Further,
based upon an encouraging commercial assessment and clinical review
of our Phase 2a data, we have developed a clinical strategy to
advance the development of FV-100 in pursuit of an indication for
the reduction of shingles-associated pain and/or post-herpetic
neuralgia in shingles patients. However, prior to fully executing
upon this strategy, we plan to obtain additional regulatory
feedback on a proposed Phase 2b protocol and regulatory pathway
that we believe can support these pain-related clinical endpoints
and indications. Finally, we are pleased that our licensee, Pfizer,
has advanced its vaccine to prevent S. aureus infections into a
Phase 1/2 clinical trial, which triggers a milestone payment to
us.”
Recent Corporate Developments
INX-189 for Chronic Hepatitis C – Next week, the Company expects
to initiate a Phase 2 clinical trial of INX-189, its nucleotide
polymerase inhibitor in development for the treatment of chronic
infections caused by hepatitis C virus (HCV), to evaluate its
safety, tolerability and antiviral activity in combination with
pegylated interferon and ribavirin in genotype 2 and 3 treatment
naïve patients. The trial, which is being conducted under an IND in
the United States, is designed to enroll approximately 90 patients.
The primary endpoint of the trial is a rapid virologic response
(RVR), defined as HCV RNA below the level of detection after 28
days of dosing. Secondary endpoints include early virologic
response (EVR), defined as HCV RNA below the level of detection
after 12 weeks of dosing, extended early virologic response (eEVR),
defined as HCV RNA below the level of detection after 28 days and
12 weeks of dosing, as well as sustained virologic response 12
(SVR12), and sustained virologic response 24 (SVR24) defined as HCV
RNA below the level of detection 12 or 24 weeks after the
completion of therapy, respectively. Patients will be randomized
across four treatment arms as follows:
- INX-189 25mg QD with pegylated
interferon and ribavirin for 12 weeks and up to 24 weeks
(n=25)
- INX-189 50 mg QD with pegylated
interferon and ribavirin for 12 weeks and up to 24 weeks
(n=25)
- INX-189 100 mg QD with pegylated
interferon and ribavirin for 12 weeks and up to 24 weeks
(n=25)
- Placebo with pegylated interferon and
ribavirin for 24 weeks (n=15)
Patients in the three treatment arms that include INX-189 with
pegylated interferon and ribavirin and achieve a eEVR will
terminate all therapy after 12 weeks. Patients in those treatment
arms that do not achieve a eEVR will continue to receive pegylated
interferon and ribavirin for an additional 12 weeks.
The Company also reported that it plans to initiate a clinical
trial this quarter to evaluate the safety, tolerability and viral
kinetics of INX-189 at doses higher than 100 mg, administered as
monotherapy, to further assess the dose response relationship
observed in a previous Phase 1b trial of INX-189.
Additionally, the Company indicated that on June 15, 2011,
European patent EP 2,097,434 that contains composition of matter
and method of use claims to a family of phosphoramidate 2’-C-methyl
guanosine nucleotides used for the treatment of chronic hepatitis C
was granted. The Company licensed the exclusive, global rights to
this patent family from Cardiff University in Wales, United Kingdom
and Katholieke Universiteit in Leuven, Belgium in November
2007.
Finally, the Company will present two abstracts at the annual
meeting of the American Association for the Study of Liver Diseases
(AASLD) in San Francisco beginning November 4, 2011. On
August 2, 2011, AASLD posted the titles of these abstracts on
its website. The titles of the two abstracts are:
- Antiviral Activity and Safety of
INX-08189, a Nucleotide Polymerase Inhibitor, Following 7-Days of
Oral Therapy in Naïve Genotype-1 Chronic HCV Patients
- Preclinical Characterization of a
Series of Highly Potent Phophorodiamidate Nucleotide Analogue
Inhibitors of Hepatitis C Polymerase.
FV-100 - The Company intends to file a protocol and other
supporting documents, including a patient reported outcomes (PRO)
dossier, to the FDA later this quarter for a proposed Phase 2b
trial of FV-100 in order to obtain feedback from the FDA on the
protocol, its PRO methodology, and a regulatory pathway that could
potentially support an indication for the reduction of
shingles-associated pain and/or the incidence of post-herpetic
neuralgia (PHN). The proposed Phase 2b trial would include
approximately 600 shingles patients with the primary endpoint being
the time to resolution of clinically significant
shingles-associated pain, and a key secondary endpoint being the
reduction in the incidence of PHN. Subject to satisfactory
regulatory review and feedback concerning these and other proposed
clinical endpoints and their potential to support an indication for
the reduction of shingles-associated pain and/or incidence of PHN,
the Company will determine whether it will initiate the proposed
Phase 2b study of FV-100 in 2012.
Staphylococcal Vaccine - The Company’s licensee and
collaborator, Pfizer, Inc., has initiated a randomized,
double-blind Phase 1/ 2 clinical trial to evaluate the safety,
tolerability, and immunogenicity of three ascending dose levels of
a 4-antigen Staphylococcus aureus (S. aureus) vaccine (SA4Ag) in
1,068 healthy adults. The vaccine contains an antigen originating
from the Company’s proprietary MSCRAMM protein platform. Pfizer is
responsible for all clinical development, manufacturing and
marketing of the vaccine. The initiation of this trial triggers a
milestone payment of $1.0 million to the Company, which is also
eligible to receive future regulatory milestones and royalties on
any future net sales.
Public Offering - In April 2011, the Company completed a public
offering of 13,182,927 shares of its common stock, at a purchase
price of $4.10 per share, for an aggregate offering amount of
$54 million. The net proceeds to the Company, after
underwriting discounts and commissions and other offering expenses,
were approximately $50.6 million.
Second Quarter 2011 Financial Results
The Company reported a net loss in the second quarter of 2011 of
$5.3 million, as compared to a net loss of $5.6 million in the
second quarter of 2010. The $0.3 million decrease in net loss in
the second quarter of 2011 was primarily the result of lower
research and development expense. Basic and diluted net loss per
share was $0.07 for the second quarter of 2011 as compared to $0.09
for the second quarter of 2010.
Revenue for the second quarter of 2011 remained the same at
$287,500 in the second quarter of both 2011 and 2010.
Research and development expense decreased to $4.6 million in
the second quarter of 2011 from $4.9 million in the second quarter
of 2010. The $0.3 million decrease was due to a $0.7 million
decrease in direct costs incurred in connection with the completion
of the FV-100 Phase 2 clinical trial, offset in part by an increase
in costs related to the clinical development of INX-189 and an
increase in non-direct expenses.
General and administrative expense remained the same at $1.0
million in the second quarter of both 2011 and 2010.
Conference Call and Webcast Information
Russell H. Plumb, President and Chief Executive Officer of
Inhibitex, and other members of management will review the
Company’s second quarter 2011 operating results and financial
position, as well as provide a general update on recent corporate
developments via a webcast and conference call today at 9:00 a.m.
EDT. To access the conference call, dial (877) 407-9210 (domestic)
or (201) 689-8049 (international). A replay of the call will be
available from 11:00 a.m. EDT on August 8, 2011 until September 7,
2011 at midnight. To access the replay, please dial (877) 660-6853
(domestic) or (201) 612-7415 (international) and reference the
account # 286 and the conference ID # 376383. A live audio webcast
of the call and the archived webcast will be available under the
News and Events category on the Inhibitex website at
http://www.inhibitex.com.
About Inhibitex
Inhibitex, Inc. is a biopharmaceutical company focused on
developing products to prevent and treat serious infectious
diseases. The Company’s clinical-stage pipeline currently includes
two Phase 2 development programs; INX-189, a nucleotide polymerase
inhibitor in development for the treatment of chronic hepatitis C
infections and FV-100, a nucleoside analogue in development for the
treatment of shingles-associated pain. The Company also has
additional HCV nucleotide polymerase inhibitors in preclinical
development and has licensed the use of its proprietary MSCRAMM®
protein platform to Pfizer for the development of a staphylococcal
vaccine, which is currently being evaluated in a Phase 1/2 clinical
trial.
For additional information about the Company, please visit
www.inhibitex.com.
Safe Harbor Statement
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
that involve substantial risks and uncertainties. All statements,
other than historical facts included in this press release,
including statements regarding: the timing of the initiation of a
Phase 2 clinical trial for INX-189 in HCV-infected genotype 2 and 3
treatment naïve patients; the Company’s plan and the timing of the
initiation of a clinical trial to evaluate the safety, tolerability
and viral kinetics of doses greater than 100 mg of INX-189
administered as monotherapy; the Company’s plan and clinical
strategy to advance the development of FV-100; the time to file a
protocol for a Phase 2b clinical trial of FV-100 and other related
submissions to the FDA and obtain feedback; the proposed design and
endpoints of a Phase 2b clinical trial of FV-100 and whether such a
study will be initiated by the Company; and the ability of FV-100
to reduce shingles-associated pain are forward looking statements.
These intentions, expectations, or results may not be achieved in
the future and various important factors could cause actual results
or events to differ materially from the forward-looking statements
that the Company makes, including the risk of: the Company, the
FDA, a data safety monitoring board, an institutional review board
(IRB), delaying, limiting, suspending or terminating the clinical
development of INX-189 or FV-100, or Pfizer delaying, limiting,
suspending or terminating the clinical development of
staphylococcal vaccine at any time for a lack of safety,
tolerability, lack of biologic activity or efficacy, commercial
viability, regulatory issues, or any other reason; our ability to
secure and use qualified third-party clinical and preclinical
research and data management organizations to assist us in
initiating and conducting planned clinical trials; third party
manufacturers not fulfilling their contractual obligations or
otherwise performing satisfactorily in the future; our ability to
manufacture and maintain sufficient quantities of preclinical and
clinical trial material on-hand to complete planned preclinical
studies and clinical trials on a timely basis; and other cautionary
statements contained elsewhere herein and in its Annual Report on
Form 10-K for the year ended December 31, 2010 and its Quarterly
Report on Form 10-Q for the period ended March 31, 2011,as filed
with the Securities and Exchange Commission, or SEC, on March 16,
2011 and May 6, 2011. Given these uncertainties, you should not
place undue reliance on these forward-looking statements, which
apply only as of the date of this press release.
There may be events in the future that the Company is unable to
predict accurately, or over which it has no control. The Company's
business, financial condition, results of operations and prospects
may change. The Company may not update these forward-looking
statements, even though its situation may change in the future,
unless it has obligations under the Federal securities laws to
update and disclose material developments related to previously
disclosed information. The Company qualifies all of the information
contained in this press release, and particularly its
forward-looking statements, by these cautionary statements.
Inhibitex® and MSCRAMM® are registered trademarks of Inhibitex,
Inc.
INHIBITEX, INC.
CONDENSED CONSOLIDATED BALANCE
SHEETS
(unaudited)
June 30, December 31, 2011 2010
ASSETS Current assets: Cash and cash equivalents $
16,713,120 $ 8,554,151 Short-term investments 33,946,530 11,014,747
Prepaid expenses and other current assets 1,016,097 599,042
Accounts receivable
74,592
178,654 Total current assets 51,750,339
20,346,594 Property and equipment, net. 828,680 1,090,029 Long-term
investments 7,297,127 — Other long-term assets
54,053 52,514 Total
assets
$ 59,930,199 $
21,489,137 LIABILITIES AND
STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $
2,305,001 $ 2,768,020 Accrued expenses 1,987,345 2,917,347 Current
portion of notes payable 243,056 243,056 Capital lease obligations
68,313 180,792 Deferred revenue 54,167 129,167 Other current
liabilities
304,663
238,703 Total current liabilities 4,962,545
6,477,085 Long-term liabilities: Notes payable, net of current
portion 182,291 303,819 Other liabilities, net of current portion
743,655 867,455
Total long-term liabilities
925,946
1,171,274 Total liabilities
5,888,491 7,648,359 Stockholders' equity: Preferred stock, $.001
par value; 5,000,000 shares authorized at June 30, 2011 and
December 31, 2010; none issued and outstanding — — Common stock,
$.001 par value; 150,000,000 shares authorized at June 31, 2011 and
December 31, 2010, respectively; 77,889,178 and 62,423,358 shares
issued and outstanding at June 30, 2011 and December 31, 2010,
respectively 77,889 62,423 Common stock warrants 8,392,001
11,145,558 Accumulated other comprehensive (loss) income 375 542
Additional paid-in capital 325,856,561 270,187,742 Accumulated
deficit
(280,285,118 )
(267,555,487 ) Total stockholders' equity
54,041,708 13,840,778
Total liabilities and stockholders' equity
$
59,930,199
$
21,489,137
INHIBITEX, INC.
CONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS
(unaudited)
Three Months Ended Six Months Ended
June 30, June 30, 2011 2010
2011 2010 Revenue: License fees and milestones
$ 37,500 $ 37,500 $ 75,000 $ 786,667 Collaborative research and
development 250,000 250,000
500,000 500,000 Total
revenue 287,500 287,500 575,000 1,286,667 Operating expense:
Research and development
4,599,325 4,915,899 11,172,135 9,705,514
General and administrative
965,132 958,834 2,162,315
1,982,875 Total operating expense 5,564,457
5,874,733 13,334,450
11,688,389 Loss from operations (5,276,957 ) (5,587,233 )
(12,759,450 ) (10,401,722 ) Other (expense) income, net (36 )
12,194 8,602 15,714 Interest income, net 18,022
16,249 21,217 34,065
Net loss
$ (5,258,971 ) $ (5,558,790 ) $ (12,729,631 ) $ (10,351,943 )
Basic and diluted net loss per
Share
$ (0.07 ) $
(0.09 ) $ (0.19
) $ (0.17 )
Weighted average shares used to compute basic and diluted
net loss per share 75,071,418 61,835,222
68,789,220 61,698,884
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jul 2023 to Jul 2024